Literature DB >> 15956384

Molecular epidemiology of endemic Clostridium difficile infection and the significance of subtypes of the United Kingdom epidemic strain (PCR ribotype 1).

Warren N Fawley1, Peter Parnell, Paul Verity, Jane Freeman, Mark H Wilcox.   

Abstract

We previously identified two subtypes of the epidemic strain Clostridium difficile PCR ribotype 1, one clindamycin-sensitive strain (arbitrarily primed PCR [AP-PCR] type Ia) and a closely related clindamycin-resistant strain (AP-PCR type Ib) in our institution. We have now carried out prospective epidemiological surveillance for 4 years, immediately following the relocation of two acute medicine wards for elderly patients (wards A and B), to determine the clinical epidemiology of subtypes of the epidemic C. difficile PCR ribotype 1 group. To maximize the chance of strain discrimination, we used three DNA fingerprinting methods, AP-PCR, ribospacer PCR (RS-PCR), and pulsed-field gel electrophoresis (PFGE), to analyze C. difficile isolates recovered from symptomatic patients and from repeated environmental samplings. On ward B the incidence of C. difficile infection correlated significantly with the prevalence of environmental C. difficile both in ward areas closely associated with patients and health care personnel (r = 0.53; P < 0.05) and in high-reach sites (r = 0.85; P < 0.05). No such relationships were found on ward A. Seventeen distinct C. difficile genotypes were identified, 17 by AP-PCR, 12 by PFGE, and 11 by RS-PCR, but only 4 of 17 genotypes caused patient infection. Isolates recovered from the hospital ward environment were much more diverse (14 genotypes). AP-PCR type Ia represented >90% of the C. difficile isolates. In addition to this genotype, only two others were isolated from both patient feces and environmental surfaces. AP-PCR type Ib (clindamycin-resistant PCR ribotype 1 clone) was not associated with any cases of C. difficile infection and was isolated from the environment on only two occasions, after having been implicated in a cluster of six C. difficile infections 5 months before this study. The disappearance of this strain implies that differences in virulence and/or selective pressures may exist for this strain and the closely related, widespread C. difficile AP-PCR type Ia strain. Our findings emphasize the need to understand the epidemiology and virulence of clinically significant strains to determine successful control measures for C. difficile infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956384      PMCID: PMC1151908          DOI: 10.1128/JCM.43.6.2685-2696.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates.

Authors:  J Freeman; M H Wilcox
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

2.  Pulsed-field gel electrophoresis of degradation-sensitive DNAs from Clostridium difficile PCR ribotype 1 strains.

Authors:  J E Corkill; R Graham; C A Hart; S Stubbs
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

3.  In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.

Authors:  M H Wilcox; W Fawley; J Freeman; J Brayson
Journal:  J Antimicrob Chemother       Date:  2000-10       Impact factor: 5.790

4.  PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes.

Authors:  S L Stubbs; J S Brazier; G L O'Neill; B I Duerden
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

5.  Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile.

Authors:  P Bidet; V Lalande; B Salauze; B Burghoffer; V Avesani; M Delmée; A Rossier; F Barbut; J C Petit
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

6.  Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.

Authors:  S Johnson; M H Samore; K A Farrow; G E Killgore; F C Tenover; D Lyras; J I Rood; P DeGirolami; A L Baltch; M E Rafferty; S M Pear; D N Gerding
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

7.  Molecular epidemiology of endemic Clostridium difficile infection.

Authors:  W N Fawley; M H Wilcox
Journal:  Epidemiol Infect       Date:  2001-06       Impact factor: 2.451

8.  Hospital disinfectants and spore formation by Clostridium difficile.

Authors:  M H Wilcox; W N Fawley
Journal:  Lancet       Date:  2000-10-14       Impact factor: 79.321

9.  Analysis of Clostridium difficile isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan.

Authors:  H Kato; N Kato; K Watanabe; T Yamamoto; K Suzuki; S Ishigo; S Kunihiro; I Nakamura; G E Killgore; S Nakamura
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 10.  The epidemiology and typing of Clostridium difficile.

Authors:  J S Brazier
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

View more
  14 in total

1.  Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals.

Authors:  Jane W Marsh; Mary M O'Leary; Kathleen A Shutt; A William Pasculle; Stuart Johnson; Dale N Gerding; Carlene A Muto; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

2.  The mosaic nature of intergenic 16S-23S rRNA spacer regions suggests rRNA operon copy number variation in Clostridium difficile strains.

Authors:  Nourkhoda Sadeghifard; Volker Gürtler; Michael Beer; Robert J Seviour
Journal:  Appl Environ Microbiol       Date:  2006-09-15       Impact factor: 4.792

3.  Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial.

Authors:  John S Fordtran
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-01

4.  Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Authors:  Thomas Akerlund; Bo Svenungsson; Asa Lagergren; Lars G Burman
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

Review 5.  Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients.

Authors:  Daniel L Raines; Fred A Lopez
Journal:  Curr Gastroenterol Rep       Date:  2011-08

6.  Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis.

Authors:  Renate J van den Berg; Inge Schaap; Kate E Templeton; Corné H W Klaassen; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2006-12-13       Impact factor: 5.948

7.  Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains.

Authors:  W N Fawley; J Freeman; C Smith; C Harmanus; R J van den Berg; E J Kuijper; M H Wilcox
Journal:  J Clin Microbiol       Date:  2008-01-23       Impact factor: 5.948

8.  Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period.

Authors:  E Sawabe; H Kato; K Osawa; T Chida; N Tojo; Y Arakawa; N Okamura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10       Impact factor: 3.267

9.  Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong.

Authors:  V C C Cheng; W C Yam; O T C Lam; J L Y Tsang; E Y F Tse; G K H Siu; J F W Chan; H Tse; K K W To; J W M Tai; P L Ho; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-06       Impact factor: 3.267

10.  Molecular Epidemiology of Clostridium difficile Infection in a Large Teaching Hospital in Thailand.

Authors:  Popchai Ngamskulrungroj; Sittinee Sanmee; Papanin Putsathit; Papanin Pusathit; Pipat Piewngam; Briony Elliott; Thomas V Riley; Pattarachai Kiratisin
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.